Cancer Registry Cancer Database
Loma Linda University Medical Center has been a regional leader in treating cancer patients since 1905 and shares the distinction of being one of only a handful of institutions throughout California with such a long history of collecting cancer. The Loma Linda Tumor Registry began collecting cancer cases in 1947, long before cancer reporting in California became a law. The original, now an archival database, contains over 33,000 cases through the year 1986.The current active database (January 1, 1987 forward) contains approximately 70,000 cases.
The Cancer Data Center collects a standardized set of core cancer data elements on each reportable cancer patient diagnosed or treated within the LLUH system and then continues to perform annual lifetime follow-up on each of these patients. The data collected are reported monthly to the California Cancer Registry, California Department of Public Health as mandated by Health & Safety Code Section 103885 and to the National Cancer Data Base annually, in conjunction with American College of Surgeons (ACOS) Cancer Program accreditation requirements. The LLUH Cancer Program has been continually accredited since 1959 and was most recently surveyed in 2018.
Data from the Cancer Registry Cancer Database offers an important tool to identify opportunities to improve the quality of the services and care provided to our cancer patients. Physicians and researchers at LLUH frequently use this data repository as an important resource for feasibility studies, grant proposals and as the data source for many ongoing studies approved by the LLUH Internal Review Board (IRB). Throughout this process, procedures and systems are in place to ensure that the confidentiality of each individual patient and their right to privacy are carefully protected.
Multidisciplinary Tumor Board – Cancer Conferences
The Medical Center now offers ten multidisciplinary Tumor Board/Cancer Conferences, coordinated by the Cancer Center’s Outcomes and Quality personnel. Tumor Board/Cancer Conferences offer physicians an opportunity to present newly diagnosed cancer cases for a prospective, multidisciplinary review.
At each of the Tumor Board/Cancer Conferences, physicians present prospective cases for consideration. The patient’s history, scans and pathology are reviewed. The findings are then discussed with further diagnostic and treatment options proposed. In 2017, a total of 2,675 prospective cases were presented at Cancer Conferences.
For more information about Tumor Board/Cancer Conferences, contact: Janet Arias at 909-651-5432
Cancer Registry Data, contact: Karen Koehn at 909-651-5458.